International Journal of Gynecological Cancer

Article	Citations
Inguinofemoral lymphadenectomy technique in 10 steps	406
The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization	192
The Cukurova score in the prediction of primary cytoreduction in ovarian cancer	141
Successful cervical cancer treatment during a monochorionic diamniotic twin pregnancy in a patient with history of preterm delivery	99
Well-differentiated papillary mesothelial tumor of the peritoneum	90
Complementary use of indocyanine green and technetium to enhance sentinel lymphadenectomy in vulvar cancer	85
Surgical technique and surgeon volume: the pursuit of data-driven outcomes	60
Best original research presented at the 25th European Congress on Gynaecological Oncology: best of ESGO 2024	60
A population-based study of outcomes in adjuvant radiotherapy for stage II endometrial carcinoma	60
Surgical staging for locally-advanced cervical cancer: the answer remains ‘NO’	60
O021/#374 Breast cancer patients are at increased risk of devoleping uterine serous cancer: implication for conseling – a seer analysis	59
Delivery of hereditary cancer genetics services to patients newly diagnosed with ovarian and endometrial cancers at three gynecologic oncology clinics in the USA, Brazil, and Mexico	58
Authors’ response to: “Methodological concerns regarding AGO score validation in low-grade ovarian cancers”	58
22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report	51
Utilization of artificial intelligence to mitigate health inequalities in gynecological cancer care	49
CERVICAL MELANOMA WITH CEREBRAL DISSEMINATION: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE IN GYNECOLOGIC ONCOLOGY	48
HIDDEN IN PLAIN SIGHT: DESMOPLASTIC SMALL ROUND CELL TUMOUR (DSRCT) PRESENTING AS A GYNAECOLOGICAL MALIGNANCY	47
HYPOFRACTIONATED RADIATION THERAPY WITH ADAPTIVE PLANNING FOR THE TREATMENT OF ENDOMETRIAL AND CERVICAL CANCER (HERA TRIAL)	47
INTRA-OPERATIVE COMPLICATIONS OF GYNECOLOGIC ONCOLOGY SURGERIES IN A TEACHING HOSPITAL IN SUB-SAHARAN AFRICA: EXPERIENCE FROM ADDIS ABABA, ETHIOPIA	45
COST-UTILITY ANALYSIS OF A MOLECULAR-INTEGRATED-PROFILE FOR WOMEN WITH (HIGH)INTERMEDIATE RISK ENDOMETRIAL CANCER - PORTEC-4A AN INTERNATIONAL, MULTICENTRE, RANDOMISED, PHASE 3 TRIAL	45
LOWER LIMB LYMPHEDEMA AFTER TREATMENT OF CERVICAL CARCINOMA AND ITS IMPACT ON QUALITY OF LIFE	44
COLPOSCOPIC-HISTOLOGIC DIAGNOSTIC AGREEMENT IN CERVICAL INTRAEPITHELIAL NEOPLASIA 2+: A FIVE-YEAR REVIEW OF COLPOSCOPIC SERVICES AT THE NATIONAL HOSPITAL ABUJA, NIGERIA COLPOSCOPIC-HISTOLOGIC DIAGNOST	43
SIGNIFICANCE & CLINICAL UTILITY OF 2-DEOXY-2-[18F] FLUORO-D-GLUCOSE-POSITRON EMISSION TOMOGRAPHY HIBRID IMAGING IN THE DIAGNOSIS & RESPONSE EVALUATION IN CERVIX CANCER.	41
THE LANDSCAPE OF VULVAR CANCER SURVIVAL AND TREATMENT CHARACTERISTICS IN BOTSWANA	41
PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-826	40

A POTENTIAL BLIND SPOT FOR ANTIBODY–DRUG CONJUGATES TARGETING FOLATE RECEPTOR-1	40
2022-RA-1495-ESGO Differential metabolism of estrogens in model cell lines and tissues of HGSOC subtypes	38
2022-RA-1001-ESGO Analysis of postoperative wound infections in malignancies of the female internal tract	37
2022-RA-1127-ESGO The efficacy of MEK inhibitors in the treatment of low-grade serous ovarian cancers: a systematic review	37
2022-RA-981-ESGO Can misdiagnosis be avoided in case of intestinal-type carcinoma of the vagina?A literature comprehensive review	37
2022-RA-630-ESGO Overexpression of PDEA1 is a predictive biomarker for platinum resistance and poor prognosis in epithelial ovarian cancer by regulating cell cycle	35
2022-RA-1690-ESGO Rare uterine cervical adenocarcinomas in salah azaiez institute: clinicopathological features	35
2022-RA-1318-ESGO Immunohistochemical profiling of macrophage subtypes in the microenvironment of ovarian tumours in young women	33
2022-RA-684-ESGO Factors affecting survival outcomes of patients with clear cell endometrial carcinoma	32
2022-RA-991-ESGO Assessment of high-risk human papillomavirus infections and cervical dysplasia in human immunodeficiency virus-positive pregnant women in germany: a prospective cross-sectional two-ce	32
2022-RA-1194-ESGO Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study	31
2022-RA-1187-ESGO Management and outcomes in high risk GTN – a regional cancer center experience	31
2022-RA-1223-ESGO Cervical cancer in pregnancy: what are the challenges?	30
2022-RA-1427-ESGO Fertility outcomes following radical trachelectomy for cervical cancer – a single centre ten year retrospective cohort study	30
2022-RA-1387-ESGO Patients with minimal residual disease at upfront debulking surgery have similar survival outcome than patients with complete cytorreduction after neoadjuvant chemotherapy	30
2022-RA-1019-ESGO Endometrial hyperplasia and cancer: results of two reference hospitals in Ankara	30
2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer	29
2022-RA-1272-ESGO Cost-effectiveness of risk-reducing surgery for breast and ovarian cancer prevention: a systematic review	29
2022-RA-1191-ESGO Efficacy of a multi-ingredient coriolus versicolor-based vaginal gel in high-risk HPV women over 40: sub-analysis of the paloma clinical trial & papilobs real-life study	29
2022-RA-421-ESGO DeflaGyn® has cytotoxic, genotoxic and apoptotic effects on human adenocancer cells: an in vitro study	28
2022-RA-1604-ESGO Efficiency of simulation program for OB/GYN residents using self-training and supervised sessions: a quantitative study	28
2022-RA-1171-ESGO Total vaginectomy for recurrent gynecological cancer. Experience in kazior	28
2022-RA-1245-ESGO Correlation between false negatives of FDG-TEP staging in locally advanced cervical cancer and FIGO 2009 clinical staging system. A retrospective single-center cohort	28
Hepatic hilum cytoreductive surgery for ovarian cancer relapse☆	27
2022-RA-1635-ESGO Accuracy of MRI imaging in preoperative stage assessment of endometrial cancer in determining extension of surgical procedure	27
Three-dimensional image of uterine transposition	27
Vulvar cancer resection with V–Y advancement flap reconstruction	27
Response to the letter regarding the article “Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA”	27
Use of quadratus lumborum block in gynecologic procedures	26
Evaluating the use of machine learning in endometrial cancer: a systematic review	26
Correspondence on “Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis” by Zhu and colleagues	26
PARSGO and UM6SS: spearheading excellence in gynecological oncology in Morocco	26
Primary ovarian leiomyosarcoma: results from an analysis by the French Sarcoma Group (Ovarian SArcoma MAnagement – OSAMA Study)	26
Growing teratoma syndrome	26
Erratum to ‘Controversies in vulvar cancer: revisiting the margin of error’ [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101678]	25
Correction: SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer	25
Ovarian reserve in young BRCA mutation carriers: a case-control analysis in reproductive-age women	24
Management of intravenous leiomyomatosis: a comprehensive review of surgical and perioperative considerations	24
Controversies in the management of mucinous ovarian tumors	24
Pocket guide based on the TNM and FIGO staging systems for classifying patients with locally advanced cervical cancer: a practical tool from the GINECO group for quick and easy management	24
Role of pre-diagnostic reproductive factors on long-term (10 years or greater) survival of epithelial ovarian cancer: The Extreme study	24
Epigenetic mechanisms of parpi resistance in ovarian cancer: A systematic review with bioinformatic analysis of clinically actionable genes	23
Real-world data from the oncosys-OVA clinical trial (NCT06117384) - experiences on genomic and functional HRD testing and molecular determinants of progression during PARP inhibitor treatment	23
Prognostic impact of low-volume metastatic disease in sentinel lymph nodes of patients with early-stage squamous cell carcinoma of the vulva	23
Distribution of molecular subgroups in advanced-stage endometrial cancer: A unicentric retrospective cohort study	22
Performance of a generative AI model in assigning FIGO 2023 endometrial cancer stages compared with clinician assessment	22
New gynaecological cancer diagnoses in women with a history of breast cancer	22
Head-to-head comparison between multidisciplinary team and artificial intelligence decision-making in advanced ovarian cancer and predictive accuracy of surgical complexity score: a pragmatic study	22
Open label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian ca	22
Mucinous ovarian cancer: A tertiary care centre experience over 10 years	22

Step-by-step type C1 robotic radical histerectomy	21
Safety of advanced laparoscopic procedures in gynaecologic oncology: a single-centre prospective cohort study	21
Daphnetin enhances cisplatin chemosensitivity in ovarian cancer by triggering proinflammatory macrophage polarization.	21
Impact of controlled ovarian stimulation and oocyte cryopreservation on recurrence and reproductive rates in patients with borderline or malignant ovarian tumours: a retrospective study from a single	21
Association between BRCA1/2 mutation and chemotherapy response score in high grade advanced ovarian cancer: a retrospective cohort study	21
Molecular profiling and clinicopathological characteristics of endometrial carcinoma in the kazakh population: first national cohort study (BR24992933)	20
Awareness of HPV and HPV vaccination in the primary care: A nationwide cross-sectional study	20
Favouring upfront surgery in primary peritoneal cancer: survival impact beyond histology	20
Re-irradiation with stereotactic radiotherapy for positive and close margins after pelvic exenteration for recurrent gynaecological cancer	20
Ovarian cancer diagnosis within 28 days after an emergency admission to hospital: a national population-based study of patient risk factors and cancer characteristics using routinely collected data in	20
Evolution of germline and somatic genetic testing in high-grade serous tubo-ovarian carcinoma: A single-centre experience in the czech republic from 2015–2023	20
Preoperative risk stratification of p53-abnormal endometrial cancer using expert ultrasound: clinical relevance of nodal staging in a multicentre retrospective study	20
Impact of the COVID-19 pandemic on service recovery and referral pathways in endometrial cancer care	19
The dark side of endometriosis: exploring different atypical and neoplastic transformations	19
PREVALENCE PATTERN OF HIGH-RISK HUMAN PAPILLOMAVIRUS GENOTYPES IN WOMEN WITH CERVICAL INTRAEPITHELIAL LESIONS IN NORTH MACEDONI	19
Clinicopathologic factors associated with recurrence in immature ovarian teratoma: A retrospective institutional study	19
Efficacy and safety of dostarlimab plus carboplatin–paclitaxel in first line patients with mismatch repair deficient or microsatellite instability-high recurrent or primary advanced endometrial cancer	19
Spectrum of molecular subtypes and their clinical associations in endometrial carcinoma: A cohort analysis	19
A minimally invasive treatment approach for early-stage uterine cervical cancer: the impact of the LACC trial	19
Implementation of enhanced recovery after surgery (ERAS) principles in gynecologic oncology: A multi-institutional evaluation from greece	19
Evaluating the feasibility of large language models in gynecologic oncology decision-making: A comparative study of chatGPT, google gemini, and bing copilot	19
To Compare The Colposcopic Findings By International Federation Of Colposcopy And Cervical Pathology (IFCPC ) Nomenclature And Swede Score For Assessment Of High Grade Cervical Lesions	18
Clinical and prognostic impact of the MELF pattern of invasion in endometrioid endometrial carcinoma: A retrospective multivariable evaluation of histopathologic and molecular correlates	18
Acceptability of the EORTC-CX24 quality of life questionnaire in a portuguese sample of cervical cancer treated patients	18
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer	18
Efficacy of a multi-ingredient coriolus versicolor-based vaginal gel on HR-HPV clearance: final results from the PALOMA 2 clinical trial	18
Sarcopenia shortens overall survival of patients with platinum-resistant recurrent ovarian cancer: inverse probability of treatment-weighting analysis	18
Optimizing sentinel lymph node detection in early-stage ovarian cancer: indocyanine green alone or combined with technetium-99m?	18
The Role Of Prehabilitation In ERAS For Gynecologic Oncology In Germany	17
Prognostic Factors In Adult Granulosa Cell Tumours Of The Ovary And Long Term Follow-Up. (The Norwegian Radium Hospital Experience 1971-2024)	17
The Silva Pattern-Based Classification And Oncological Outcomes In Women Undergoing Fertility-Sparing Surgery For Early-Stage Cervical Cancer	17
Secondary Debulking Followed By Localised Radiotherapy In Patients With Oligometastatic Recurrent Ovarian Cancer – A Case Series Of Two International Cancer Centres	17
Evaluating The Implementation And Outcomes Of The Tumor-First Testing Strategy For BRCA1/2 Pathogenic Variants In Ovarian Cancer Patients: A Center-Wide Analysis	17
Prospective Multicentre Evaluation Of Secondary Cytoreductive Surgery In The Era Of PARP-Inhibitors (CONCEPT) In Relapsed Epithelial Ovarian Cancer	17
Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology Registry	17
A Multivariable Prognostic Analysis For Survival Outcomes In Women With Epithelial Ovarian Cancer - A North Indian Single Centre Study	17
SPLEEN PRESERVING EXTENSIVE CYTOREDUCTIVE SURGERY	17
Does The Origin Of Ovarian Cancer Influence Outcomes?	17
Histological Findings After Completion Hysterectomy And Clinical Outcome Following Conservative Treatment Of Endometrial Carcinoma	16
Impact Of Surgery On Survival Outcomes In Locally Advanced Cervical Cancer Patients With Partial Response After Primary Chemoradiotherapy	16
Perioperative Outcomes Of Heated Intraperitoneal Chemotherapy For Patients Enrolled In The Feasibility Phase Of A Randomized Controlled Trial: Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy	16
Surgical Release Of The Pudendal Nerve By Robotic Approach In 10 Steps	16
Trop-2 Expression In Cervical Carcinoma (CX) - A Possible Target For The Antibody Drug Conjugate Sacituzumab	16
Assessment Of The Predictive Role Of Khorana Score And Genomic Profiling In Ovarian Cancer-Related Venous Thromboembolism	16
Patient-initiated follow-up in low-risk endometrial cancer after surgery: a systematic review	16
The Prognostic And Predictive Value Of Cardiophrenic Lymph Nodes In Patients Receiving Hyperthermic Intraperitoneal Chemotherapy For Ovarian Cancer In The OVHIPEC-1 Trial	15
Impact Of Preoperative Conization On The Prognosis Of Cervical Cancer Patients Undergoing Open Abdominal Radical Hysterectomy	15
Excision Of Retroperitoneal Mass - Laparoscopic Management Of Iliac Artery Injury	15
Survival Prediction And Mortality Risk Stratification In Ovarian Cancer After NACT: PRGS Outperforms CRS Regression Scoring	15
PROGNOSTIC FACTORS BASED ON THE MOLECULAR CLASSIFICATION OF ENDOMETRIAL CANCER: SINGLE INSTITUTION STUDY	14
Surgical Treatment Of Advanced Ovarian Cancer: Experience From A Brazilian Cancer Center (Barretos Cancer Hospital) In 2023	14
Does Sentinel Node Know The Cancer Origin? Comparing Sentinel Lymph Nodes Localization In Endometrial And Cervical Cancer	14
Clinical Significance Of Low Volume Lymph Node Metastasis In Early Stage Cervical Cancer: A Single Centre Case Series	14
The “N-PLUS/NOGGO-Ov53/ENGOT-Ov62-STUDY” To De-Escalate Chemotherapy In Ovarian Cancer: Comparing 3 Vs. 6 Cycles Of Platinum-Based Chemotherapy After Complete Tumor Resection Followed By Niraparib Mai	14
Early-Stage Breast Cancer: A Detailed Examination Of Clinicopathological Features	14
Advanced Techniques In Pelvic Exenteration For Cervical Cancer: A Case-Based Surgical Guide	14
The Role Of Second-Look Surgery In Recurrent Ovarian Cancer Based On The Type Of Relapse	14
A fully next-generation sequencing-based method of classifying molecular sub-types of endometrial cancer retains prognostic value and expands biomarker targets	14
A Young Woman Presenting Virilization With Ovarian Mass: A Case Report Of Rare Disease - Ovarian Steroid Tumor	14
Impact Of Ascites And Peritoneal Metastatic Lesion Volumes, Measured By Newly Developed Deep Learning-Based Algorithm, In Advanced Epithelial Ovarian Cancer	14
Comparative Outcomes Of Excision And Active Surveillance For Cervical Intraepithelial Neoplasia 2 In Women Under 35	14
Epithelial ovarian cancer and borderline tumors during pregnancy: a report from the International Network on Cancer, Infertility, and Pregnancy	13
Squamous Cell Carcinoma Arising In Mature Cystic Teratomas: A Case Series Review Of Presentation, Treatment, And Prognosis	13
1173 Diagnostics and treatment of uterine sarcomas: challenges of a low-volume tertiary centre	13
EV018/#1081  Mapping BTLA immunoreceptor signalling pathways in T-cells	13
461 HBOC and lynch syndrome: ai-powered multi-platform analysis of social media activity	13
Performance of molecular classification in predicting oncologic outcomes of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer	13
Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer	13
2022-RA-828-ESGO A case of 19 years old, female with malignant spindle cell neoplasm; pelvic monophasic synovial sarcoma arising from the pelvic ligaments	13
#923 PD-1/PD-L1 pathway expression in imiquimod treatment of high-grade cervical lesions	13
EP268/#152  Exploring the impact of surgical interventions and identifying risk factors for recurrence in borderline ovarian tumors	13
#840 Neutrophilic inflammation in squamous cell vulvar carcinoma	13
Computed tomography–based prediction of interval cytoreduction in advanced ovarian cancer	13
Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma	13
#766 21st century robotic radical hysterectomy should follow strict oncologic principles, have quality control and be nerve-sparring. puppeteer, stapler, bath, dual insufflation, blue and green to the	13
#136 Sentinel lymph node mapping in early-stage ovarian cancer: equivalence of cervix vs utero-ovarian ligament injection for pelvic sentinel lymph node mapping	13
EP236/#459  Developing a whole exome sequencing-based homologous recombination deficiency test of epithelial ovarian cancer	13
EP017/#738  Insights from ovarian cancer patients’ rapid autopsy shed light on mechanisms of CD4+ T cell-mediated pre-metastatic niche formation through the STAT3 axis	12
EP186/#742 Is it time to test all endometrial carcinomas for P53 mutation?	12
899 Node-positive carcinoma of vulva treated with curative-intent radiotherapy: reported outcomes from a large single Australian institution	12

#150 E-Cadherin modulates cervical cancer progression by regulating EMT progression via the EGFR signaling pathway	12
851 Exploring the interplay between the CXCR4 pathway and immune response in serous papillary ovarian tumors	12
539 Survival impact of selective lymph node biopsy in patients with early-stage cervical cancer	12
240 TGF-beta gene polymorphism and ovarian cancer susceptibility	12
398 Prognosis in locally advanced cervical cancer with pelvic lymph node metastases	12
#909 Fertility -preserving approach in P53 mutant grade 2 endometrioid endometrial canser- cases presentation	12
EV420/#706  To evaluate clinical effectiveness, safety and patients experience with apixaban, for extended VTE prophylaxis, after major surgeries for gynaecologic malignancies	12
146 Granulosa cell tumors of the ovary: a retrospective study	12
EV127/#1083  Is consolidation therapy effective in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment?	12
#1029 Cervical cancer prevention among ukrainian refugees during the first six months after the beginning of the war: the european network of young gynae oncologists (ENYGO) survey results	12
#305 (R)etrospective (A)nalysis of the correlation of (M)SI-H/DMMR status and response to therapy for (E)ndometrial cancer: RAME study, a multicenter experience	12
EP350/#408  Complete visualization of transformation zone in colposcopy using estradiol or misoprostol: a clinical trial	12
EV149/#796  Assessment of sentinel lymph node mapping algorithm for staging intermediate to high-risk endometrial cancers	12
EP420/#482  Prognostic value of perineural invasion in vulvar cancer	12
#393 A rarely seen squamous cell carcinoma arising in the dermoid cyst	11
#963 Association of HPV and sexually transmitted infections among patients with genital warts and asymptomatic individuals: a cross-sectional study	11
1310 Clinical and survival associations of arid1a mutations in endometrioid uterine cancer: a TCGA analysis	11
949 Peritoneal carcinoma index (PCI) as a predictor for small bowel resection in advanced ovarian carcinoma surgery	11
EP188/#651 Combined nursing and medical quality improvement initiative to incorporate gynaecological oncology tumor board summaries into electronic health records at a tertiary cancer centre in Singap	11
EP281/#1130 Consolidation hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer: review of a single center experience	11
328 RENI-1: a prospective, multicenter real-world study of niraparib as first-line maintenance therapy in newly diagnosed advanced ovarian cancer	11
281 MRI radiomics captures early treatment response in patient-derived organoid endometrial cancer mouse models	11
797 Beyond surgery: analysing healthcare professionals satisfaction in eras implementation process	11
298 Introducing a prehabilitation programme into the care of gynaecological oncology patients – a single institution experience	11
#1032 Addressing women’s sexual health after gynecological cancer primary treatment	11
908 ‘No-Touch’ intraoperative containment technique in a case of robotic assisted laparoscopic cytoreduction for recurrent ovarian cancer	11
#712 Adjuvant treatment after radical hysterectomy for early cervical cancer	11
EV390/#965  Spectrum of somatic mutations in uterine sarcoma: a single center study	11
#597 Possible epigenetic changes that could drive platinum resistance in high grade serous ovarian carcinoma: data from an in-vitro treatment model	11
EP002/#234  Results of clinical research (PRUM-IBIO study): establishment of prognostic biomarkers for uterine mesenchymal tumors	11
EP100/#579  Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiation in stage IIIC cervical cancer without parametrial invasion	11
#805 An update of a systematic literature review of health state utility values in patients with platinum-resistant or -refractory ovarian cancer	11
EV402/#953  Barriers to cervical cancer screening in an inner-city obstetrical population: a mixed methods pilot study	11
PR070/#391  Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)	11
506 Consolidation courses in low-risk gestational trophoblastic neoplasia and relapse rate: a MITO-9 study	11
PO003/#269  Ignite: a phase II signal-seeking trial of adavosertib targeting recurrent high grade serous ovarian cancer with cyclin E1 over-expression with and without gene amplification	10
996 Understanding symptom appraisal and help-seeking in people with symptoms suggestive of endometrial cancer: a mixed methods study	10
EV267/#1245  Enhancing adnexal mass diagnosis: US O-RADS evaluation and clinical correlations	10
803 Efficacy and safety of bevacizumab following prior anti-angiogenic treatment in patients with second-line platinum- based chemotherapy in recurrent ovarian cancer – a subgroup analysis of the AGO-	10
#328 Frequency and pattern of relapse following adjuvant pelvic radiotherapy or vaginal brachytherapy for high-intermediate risk endometrioid endometrial cancer	10
PR085/#158  Predictors of lifetime cervical cancer screening and association with social determinants of health: cross-sectional evidence from the Canadian longitudinal study on aging	10
EP179/#1170 High treatment default and low compliance creates ovarian cancer care gap : snapshot annual audit of ovarian cancers at a tertiary centre in a lmic	10
EV031/#1651  Clinical characteristics and prognosis of primary mucinous ovarian cancer versus clear cell carcinoma: a 4-year retrospective analysis in Vietnam	10
#733 Choriocarcinoma in young patients after sectio caesarea: a case report	10
EP387/#661 Pelvic exenteration in gynecologic cancers: a single center study from India	10
SF038/#1037 Splenic mobilization and resections in cytoreductive surgery for ovarian cancer	10
11/#620 Oncologic outcome of patients with stage I immature teratoma treated with surveillance or adjuvant chemotherapy	10
1012 Push and pull factors associated with engagement with prehabilitation for ovarian cancer: a qualitative review	10
#835 Sexual satisfaction after surgery for endometrial cancer: a comparison of the effects of lymphadenectomy on rehabilitation and quality of life. A retrospective analysis at jena university hospita	10
PR016/#982  Development and validation of 18F-FDG PET/CT-based models predicting complete cytoreduction during secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer	10
EP336/#874  Semiquantitative lymphoscintigraphy in gynecologic cancer patients with lower extremity lymphedema: prediction of short-term outcome after lymphaticovenous anastomosis	10
775 Prevalence and determinants of anemia in cervical cancer patients: a one-year retrospective study	10
SF033/#1181  Instillation of ICG dye into ureters for intra-operative identification during robotic surgery for gynecologic malignancies	9
EP423/#119  Prognostic factors and clinical outcomes in patients with vulvar cancer: a 15-year retrospective study	9
#72 Ovarian cancer audit of a UK tertiary centre over the past 3 years	9
EP117/#831  Are we underutilizing stereotactic body radiotherapy in the treatment of oligometastatic uterine cancer?	9
347 Risk factors of bone marrow toxicities in ovarian cancer patients treated with parp inhibitors	9
722 Imaging-guided preoperative localization of perisplenic isolated local recurrence of ovarian cancer using a combined harpoon and radioactive tracer technique	9
480 Navigating the uncommon: a twin pregnancy brought to term with complete hydatidiform mole and coexisting fetus	9
535 Locally advanced cervical cancer: correlation between pelvic bone radiation dose and acute hematological toxicity	9
#1019 Cervical cancer in young women: epidemiological features, therapeutic characteristics and prognosis	9
FF003/#788 Radical trachelectomy with laterally extended endopelvic resection for locally advanced cervical cancer	9
41/#564 Integrating cervical cancer screening with voluntary family planning in Mozambique: the mulher study	9
362 OPTIMUS: optimising cardiovascular health in endometrial cancer survivors- the impact on quality of life and barriers to change	9
SF005/#545  Therapeutic effect of extended pelvic lymphadenectomy in cervical cancer: a propensity-score matched cohort study	9
976 The impact of Covid-19 on the care of endometrial and ovarian cancer: a population-based study in the Netherlands	9
#1026 Predictors of psychological distress in tunisian women undergoing chemotherapy for gynaecological cancer	9
EV358/#753  Establishing GO Hildas: a diversity-focused co-production group in gynaeoncology to improve health equity	9
1103 Combinatory analysis of CfDNA and CtDNA as a predictive and follow up tool to improve endometrial cancer management	9
304 Exploring mean platelet volume as a survival indicator in ovarian clear cell carcinoma: a retrospective analysis and random forest model assessment	9
668 Clinicopathologic profile of endometrial cancer in Prof. Dr. I.G.N.G Ngoerah general hospital denpasar Bali During the period of January 2022 – october 2023	9
PO005/#134  Risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in real-world ovarian cancer (AOC) patients treated with first- or second-line maintenance PARP inhibitors (PARPI)	9
1282 Lymph node recurrences in ovarian cancer: safe techniques in the minimally invasive approach	9
EP260/#796 Robotic primary cytoreductive surgery for advanced stage ovarian cancer: a pilot study, feasibility and outcomes	9
#237 Para vulvar proximal epithelioid sarcoma with yolk sac differentiation: a case report	9
EV457/#362  The psychosocial impact of ovarian cancer: distress, fears and unmet needs	9
Author index	9
#471 PARP-inhibitors can be applied together with tumor treating fields (TTFields) to prolong survival in an ovarian cancer mouse model	9
EP071/#406 Assessing geographic variation in rates of recurrent or metastatic cervical cancer (based on commencement of systemic therapy) among medicaid enrollees	9
EP397/#844 Survivorship needs of women following treatment for gynaecological cancer – learning from the patient experience to develop future models of care	9
EP104/#389 Genomic profiling of circulating tumor DNA from peritoneal fluid in endometrial cancer	9
522 Comparison of efficacy and adverse events of 2 ACT-D regimens in the treatment of low-risk gestational trophoblastic neoplasia: a retrospective study	9
EP259/#509  Genetic counseling and testing for epithelial ovarian cancer in a diverse patient population	9
EV021/#894  Mutational analysis of circulating tumour DNA (ctDNA) in high grade serous ovarian cancer (HGSC) using cancer personalised profiling by deep sequencing (CAPP-seq)	9
1346 Impact of obesity on sentinel lymph node mapping in patients with endometrial intraepithelial neoplasia undergoing robotic surgery	9
EP268/#553 Side effects and decision-making factors associated with maintenance therapy: patient preferences using a visual scale analog (VAS) assessment	8
EP378/#781 Advantages of laparoscopy in gynecologic surgery in elderly patients	8
Surgical modality non-inferiority testing with an intensification of adjuvant treatments: a missed opportunity	8
37/#877 Hormonal biomarkers remain prognostic relevant within the molecular classification in endometrial cancer	8
EP275/#524 Retrospective analysis of total parietal peritonectomy without systematic lymphadenectomy for advanced epithelial ovarian cancer	8
Improvement in radiation techniques for locally advanced cervical cancer during the last two decades	8
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)	8
EP248/#494 3 years survival and risk of cancer progression and death caused by ovarian cancer in Georgia	8
EP101/#503 Relevance of genomic instability score, tumor mutational burden, and tumor infiltrating lymphocytes as biomarkers in uterine serous carcinoma	8
Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeins	8